TRIM9 and neoplasm: Moreover, immunostaining analysis further demonstrated that recurrent patients exhibited enhanced Smad2/3 expression in tumor tissues, when compared to non-recurrent patients (Fig. 3B), indicating the potential role of Smad2/3 in TRIM9-assocaited tumor progression.